Merck KGaA acquired Serono International S.A. for CHF 16.6 billion (~$13.3 billion) in an all-cash transaction, gaining a leading biotech company focused on fertility, multiple sclerosis (Rebif), and growth disorders. The deal transformed Merck from a mid-sized chemicals/pharma company into a top-20 global pharmaceutical player.